异基因骨髓移植后患者血浆中可溶性Fas配体水平的变化(英文)  

Plasma Soluble Fas Ligand Levels in Hemopathic Patients Undergoing Allogeneic Bone Marrow Transplantation

作　　者：黄晓军[1] 万峻[1] 陆道培[1] 

机构地区：[1]北京大学人民医院血液病研究所,北京100044

出　　处：《中国实验血液学杂志》2001年第3期247-250,共4页Journal of Experimental Hematology

摘　　要：为明确可溶性Fas配体 (sFasL)与急性移植物抗宿主病 (aGVHD)及感染的关系 ,采用ELISA方法检测了 13名异基因骨髓移植受者移植前后 84份血浆标本sFasL水平 ,比较其与临床发生aGVHD和感染的相关性。结果表明 :发生Ⅱ -Ⅳ级aGVHD时受者血浆sFasL水平高于 0 -Ⅰ级aGVHD者 ;发生相同aGVHD情况下有感染的sFasL水平与无感染时相比无明显差异 ;7名发生Ⅱ -Ⅳ级aGVHD的患者在移植前的sFasL水平较 0 -Ⅰ级aGVHD者低。移植后受者血浆sFasL水平对于aGVHD的诊断有重要意义 ,可作为aGVHD与感染相鉴别的指标 ,而移植前较高水平的sFasL对患者有一定保护作用 。To evaluate the implications of soluble Fas ligand (sFasL) in acute graft-versus-host disease (aGVHD) and discriminating symptoms of aGVHD from those of infection, plasma levels of sFasL were assessed in 84 plasma samples from 13 patients who had undergone allogeneic BMT by using a sandwich enzyme-linked immunological assay (ELISA). Plasma sFasL levels of the patients before BMT and at different time points during the post-BMT period were measured. Three points were concluded: ① Plasma sFasL levels were higher in patients with grade Ⅱ-Ⅳ aGVHD than in those with grade 0 or Ⅰ aGVHD. ② Plasma sFasL levels in patients with infection were not statistically different from those in patients without infection. ③ In seven patients with grade Ⅱ-Ⅳ aGVHD, the plasma sFasL levels at pre-BMT were much lower than those of the six patients with 0 or Ⅰ grade aGVHD. sFasL may be useful for the diagnosis of aGVHD and for differentiating aGVHD from other BMT related complications such as infection.

关 键 词：可溶性性Fas配体 SFASL 异基因骨髓移植 急性移植物抗宿主病 AGVHD 

分 类 号：R457.7[医药卫生—治疗学]